ProQR Therapeutics

ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target

Shots: ProQR is eligible to receive ~$115M up front and milestone along with royalties on the sales of any resulting products during the royalty term and gets the right to receive a percentage of equity in the form of Yarrow shares Yarrow has in-licensed exclusive… Read More »ProQR Therapeutics Signs an Exclusive Worldwide License Agreement with Yarrow to Develop Therapies for Non-Ophthalmic Target